Development
Takeda Pharmaceutical Company Limited
TAK
$15.52
$0.211.37%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -3.21% | -0.50% | 2.75% | -3.85% | -1.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.21% | -0.50% | 2.75% | -3.85% | -1.93% |
| Cost of Revenue | 7.89% | 7.55% | 3.49% | -16.78% | -3.77% |
| Gross Profit | -8.11% | -4.03% | 2.44% | 3.50% | -1.10% |
| SG&A Expenses | -2.58% | -2.77% | 1.17% | 0.14% | -8.51% |
| Depreciation & Amortization | -3.24% | 61.34% | -1.93% | -29.97% | -7.46% |
| Other Operating Expenses | -19.67% | 45.32% | 19.14% | -178.90% | 28.05% |
| Total Operating Expenses | 1.22% | 16.33% | 3.10% | -14.16% | -2.47% |
| Operating Income | -31.82% | -145.17% | 1.06% | 100.54% | 1.71% |
| Income Before Tax | -45.39% | -242.16% | -18.02% | 177.86% | 19.64% |
| Income Tax Expenses | -254.30% | -1,729.43% | -14.64% | 134.53% | -167.27% |
| Earnings from Continuing Operations | -15.22% | -174.30% | -19.64% | 340.38% | 66.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -56.35% | -664.09% | -48.33% | -110.32% | 65.24% |
| Net Income | -15.23% | -174.38% | -19.65% | 340.73% | 66.21% |
| EBIT | -31.82% | -145.17% | 1.06% | 100.54% | 1.71% |
| EBITDA | -13.89% | -53.17% | 1.66% | 46.27% | -1.03% |
| EPS Basic | -16.01% | -173.75% | -20.10% | 340.70% | 67.33% |
| Normalized Basic EPS | -45.92% | -241.07% | -20.99% | 407.36% | 20.56% |
| EPS Diluted | -16.02% | -174.32% | -20.19% | 340.54% | 66.70% |
| Normalized Diluted EPS | -45.93% | -242.13% | -21.09% | 407.36% | 20.10% |
| Average Basic Shares Outstanding | 0.92% | 0.83% | 0.56% | 0.08% | -0.68% |
| Average Diluted Shares Outstanding | 0.94% | 0.10% | 0.69% | 0.08% | -0.29% |
| Dividend Per Share | -- | -0.14% | -- | -12.19% | -- |
| Payout Ratio | 0.21% | -2.05% | 0.19% | 1.36% | -0.52% |